All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Lisocabtagene maraleucel receives EC approval for the treatment of adult patients with R/R LBCL after one prior therapy

May 5, 2023
Learning objective: After reading this article, learners will be able to cite a new clinical development in LBCL.

On May 3, 2023, it was announced that lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, received approval from the European Commission (EC) for the treatment of adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma Grade 3B (FL3B) after one prior therapy.1

This approval is based on results from the phase III TRANSFORM trial (NCT03575351),1 in which liso-cel was compared with standard therapy. Below, we report the key data:

  • In an interim analysis with median follow up of 6.2 months, event-free survival (EFS) for liso-cel compared with standard therapy was 10.1 months vs 2.3 months, respectively (HR, 0.349; 95% confidence interval [CI], 0.229–0.530; p < 0.0001).1
  • In the primary analysis at a median follow-up of 17.5 months, EFS was not reached for liso-cel vs 2.4 months for standard therapy (95% CI, 9.5–NR vs 2.2–4.9).1
  • Liso-cel achieved a complete response rate of 73.9% compared with 43.5% for standard therapy.1
  • Median progression-free survival was not met (95% CI, 12.6–NR) for liso-cel vs 6.2 months (95% CI, 4.3–8.6) for standard therapy (HR, 0.400; 95% CI, 0.261–0.615).1

Liso-cel showed improved EFS compared to standard of care with a manageable safety profile.1 These data support the use of liso-cel as a second-line treatment for patients with primary refractory or early relapsed LBCL.2

  1. Bristol Myers Squibb receives European Commission approval for CAR T cell therapy breyanzi (lisocabtagene maraleucel) for relapsed or refractory large B-cell lymphoma after one prior therapy. Published May 3, 2023. Accessed on May 4, 2023.
  2. Lisocabtagene maraleucel as second-line therapy for adults of the phase III TRANSFORM trial. Published Mar 20, 2023. Accessed on May 4, 2023.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

What kind of 1L DLBCL patients should now be treated with Pola-R-CHP (choose all options that apply)?
4 votes - 1 day left ...


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox